CN1123672A - Boligan compound polyose and its identification - Google Patents
Boligan compound polyose and its identification Download PDFInfo
- Publication number
- CN1123672A CN1123672A CN 94113003 CN94113003A CN1123672A CN 1123672 A CN1123672 A CN 1123672A CN 94113003 CN94113003 CN 94113003 CN 94113003 A CN94113003 A CN 94113003A CN 1123672 A CN1123672 A CN 1123672A
- Authority
- CN
- China
- Prior art keywords
- polyose
- boligan
- compound polyose
- compound
- hydrochloric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The compound polyose for treating hepatitis, especially hepatitis B with obvious curative effect contains ginseng polyose, astragalus polyose and liquorice polyose, which are extracted respectively from ginseng, astragalus root and liquorice root through water extracting and alcohol settling. A thin-layer chromatographic hydrochloric acid vapour hydrolysis is used for its quick discrimination.
Description
The present invention relates to a kind of compound polyose and discrimination method thereof, for clinical treatment hepatitis provides a kind of novel medicament, for medicine inspection department differentiates that compound polyose provides a kind of new method.
The medicinal part that Boligan compound polyose system extracts from ancient proved recipe " Bao Yuantang ", " Bao Yuantang " is traditional prescription (bright Xiaoshan Wei Zhi work " universal love heart mirror " three volumes) that motherland's medical science " is controlled the bean skin ulcer deficiency of vital energy and fallen into the person ", prescription is mainly with Radix Ginseng, the Radix Astragali, Radix Glycyrrhizae is formed, be recited as " panacea that removes scorching flesh heat " modern medicine study according to Compendium of Material Medica and show that three flavor Chinese medicines all are main strengthening the body resistance medicines in this prescription, the ginseng polysaccharide, astragalus polysaccharides, Angelica Polysaccharide is respectively Radix Ginseng, the Radix Astragali, the bioactive ingredients that extracts in the Radix Glycyrrhizae, closely related with the strengthening the body resistance effect.The pharmacological action that the prior art branch is penetrated these three kinds of polysaccharide possesses some special knowledge, and they have effects such as immunomodulating, anti-hepatic injury, antiviral, leukocyte increasing.
Because " Bao Yuantang " is the crude drug in whole water decoction, un-extracted is refining, and multiple composition mixes, and drug effect is slow, takes inconvenience.Prior art is few to the application record of " Bao Yuantang ", is useful on " angiocardiopathy and aplastic anemia " report, but is not used in the report of treatment hepatitis.In the process of producing the Boligan compound polyose, must carry out the discriminating of compound polyose, prior art adopts back hydrolysis (Huang Qiaoshu etc.: the research of astragalus polysaccharides to the discrimination method of polysaccharide, Acta Pharmaceutica Sinica, the 17 3 phases of volume) the present invention adopts thin layer chromatography hydrochloric acid vapour Hydrolyze method to the discrimination method of compound polyose, this method hydrolysis is complete, and hydrolysis time is short, reliable results.
The objective of the invention is to development and utilization motherland pools of traditional Chinese medicine, develop effectively and the little treatment hepatitis new drug of toxic and side effects.The present invention system extracts refining drug with composition Boligan compound polyose from Radix Ginseng, the Radix Astragali, Radix Glycyrrhizae, form (adopting medicinal part and the bonded nomenclature principle of function, called after Boligan compound polyose) by ginseng polysaccharide, astragalus polysaccharides, Angelica Polysaccharide.Overcome the decoction polysaccharide component and other composition mixes, drug effect is slow, consumption is big, treatment shortcomings such as specificity is not strong, for clinically providing a safety, effectively having treated the newtype drug of hepatitis, the discriminating for compound polyose simultaneously provides quick, accurate, an easy discrimination method.
The Boligan compound polyose is made up of ginseng polysaccharide, astragalus polysaccharides, Angelica Polysaccharide, is raw material with Radix Ginseng, the Radix Astragali, Radix Glycyrrhizae, and through water extraction, technologies such as alcohol precipitation are made with extra care and formed, and can make different dosage forms such as capsule, granule, injection.Its thin layer chromatography discrimination method is as follows: preparation Boligan compound polyose test liquid, and according to thin layer chromatography point sample (57 pages of appendix of Pharmacopoeia of People's Republic of China nineteen ninety version).Place the hydrochloric acid vapour water in the cup on the boiling water bath to separate lamellae, take out and to fling to hydrochloric acid, launch, colour developing, observe chromatograph with developing solvent, with the corresponding position of reference substance chromatograph on show identical orange red speckle, confirm that promptly test sample is the Boligan compound polyose.
Boligan compound polyose of the present invention and thin layer chromatography hydrochloric acid vapour hydrolysis discrimination method thereof are not seen domestic and foreign literature and patent report as yet.
That the Boligan compound polyose is formed is clear and definite, stable content, raw material are easy to get, are convenient to produce, and discrimination method is accurate, quick, easy and simple to handle, can make multiple dosage form for clinical practice.
Pharmacology and toxicological test show that the Boligan compound polyose can obviously suppress DHB; Can resist by CCl
4The mouse liver transaminase who causes raises; Can improve the phagocytic activity of mouse monokaryon macrophage, point out it to have anti-hepatitis virus, transaminase lowering, the immunocompetent effect of promotion.Clinical practice is in hepatitis, and especially the treatment of hepatitis B has good effect, can improve body's immunological function, and is safe in utilization, do not see untoward reaction.
Embodiment: 1, prescription is formed: Radix Astragali 3kg Radix Ginseng 2kg Radix Glycyrrhizae 1kg2, preparation method: after above medicine is pulverized mixing, be refined into Boligan compound polyose 200g through technologies such as water extraction, dialysis, ultrafiltration, alcohol precipitations.3, discrimination method:
Get this product 0.1g, add water 5ml, heating for dissolving 20 minutes, put cold, centrifugal, get supernatant 2ml and make test liquid, other gets the arabinose reference substance and adds water to make the solution that every 1ml contains 0.5mg be reference substance solution, according to thin layer chromatography (57 pages of appendix of Pharmacopoeia of People's Republic of China nineteen ninety version) test, draw above-mentioned two kinds of each 20ul of solution, idea is same respectively contains on the silica gel g thin-layer plate that 0.4% Sodium Tvlose is a binding agent, puts on the boiling water bath hydrochloric acid vapour water in the cup and separates 30 minutes, takes out, fling to hydrochloric acid, with phenol: water (3: 1) is that developing solvent launches, and takes out, and dries, spray is with the aniline-phthalic acid test solution, about 10 minutes of 110 ℃ of bakings.During the test sample color is dived, with the corresponding position of Ah position's sugared reference substance chromatograph of uncle on the identical orange red speckle of amount.
Claims (4)
1, a kind of Boligan compound polyose is characterized in that with Radix Ginseng, the Radix Astragali, Radix Glycyrrhizae be raw material through extracting the refining compound polyose that forms, and what it is characterized in that this compound polyose consists of ginseng polysaccharide, astragalus polysaccharides, Angelica Polysaccharide.
2, a kind of thin layer chromatography discrimination method of Boligan compound polyose is characterized in that adopting thin layer chromatography hydrochloric acid vapour Hydrolyze method.
3,, it is characterized in that this medicine can make dosage forms such as capsule, granule, injection according to the described Boligan compound polyose of claim 1.
4, according to claim 2 described Boligan compound polyose thin layer chromatography hydrochloric acid vapour hydrolysis discrimination methods, it is characterized in that placing the hydrochloric acid vapour water in the cup on the boiling water bath to separate compound polyose lamellae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94113003 CN1123672A (en) | 1994-11-30 | 1994-11-30 | Boligan compound polyose and its identification |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94113003 CN1123672A (en) | 1994-11-30 | 1994-11-30 | Boligan compound polyose and its identification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1123672A true CN1123672A (en) | 1996-06-05 |
Family
ID=5036467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 94113003 Pending CN1123672A (en) | 1994-11-30 | 1994-11-30 | Boligan compound polyose and its identification |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1123672A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100441197C (en) * | 2004-03-17 | 2008-12-10 | 天津天士力制药股份有限公司 | Medicinal composition containing panax ginseng polysaccharide |
| CN1985873B (en) * | 2005-12-19 | 2011-02-09 | 山东轩竹医药科技有限公司 | Medicine composition of glycyrrhizic acid or its salt, ginseng and astragalus root |
| CN109833342A (en) * | 2019-02-27 | 2019-06-04 | 李军旗 | Four gas balls (dissipate, capsule, oral solution, soup) formula |
-
1994
- 1994-11-30 CN CN 94113003 patent/CN1123672A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100441197C (en) * | 2004-03-17 | 2008-12-10 | 天津天士力制药股份有限公司 | Medicinal composition containing panax ginseng polysaccharide |
| CN1985873B (en) * | 2005-12-19 | 2011-02-09 | 山东轩竹医药科技有限公司 | Medicine composition of glycyrrhizic acid or its salt, ginseng and astragalus root |
| CN109833342A (en) * | 2019-02-27 | 2019-06-04 | 李军旗 | Four gas balls (dissipate, capsule, oral solution, soup) formula |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016312007B2 (en) | Shenlingbaizhu granules and preparation method thereof | |
| CN112972547B (en) | Traditional Chinese medicine composition for treating qi and blood deficiency syndrome and preparation method and application thereof | |
| CN110455965A (en) | The preparation method and its HPLC fingerprint of pharmaceutical composition | |
| CN104288245A (en) | Pharmaceutical composition having functions of defying age and enhancing physique, preparation method and detection method thereof | |
| CN101199672A (en) | Chinese medicine health care wine containing function of regulating human body immunity | |
| CN103405632B (en) | Oral liquid mainly comprising radix scrophulariae, radix ophiopogonis, ginseng and manis pentadactyla, preparation method thereof, and detection method of quality standard | |
| US11000569B2 (en) | Medicament for use in treating fatty liver, hepatitis and cirrhosis | |
| CN1123672A (en) | Boligan compound polyose and its identification | |
| CN104138468A (en) | Application of traditional Chinese medicine compound in preparing of lipid-lowering drugs | |
| CN102258626B (en) | Traditional Chinese medicine compound Tenghuanglin, preparation method and application thereof | |
| CN101884661A (en) | Traditional Chinese medical preparation containing leeches and astragalus and used for treating cardiovascular and cerebrovascular diseases | |
| CN112138084B (en) | Traditional Chinese medicine composition for treating bronchiectasis qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN103417906B (en) | Cantharides Chinese medicine composition and the purposes of preparation in preparation medicament for treatment of depression thereof | |
| CN113599471A (en) | Traditional Chinese medicine granules for primary lung cancer and production process thereof | |
| CN107669751A (en) | A kind of clarification process and method of quality control of the pharmaceutical composition that there is treatment red blood trace on face to act on | |
| CN102302542A (en) | Chinese medicinal oral liquid for treating cancers | |
| CN101274053B (en) | Detection method of capsules for curing waist pain | |
| CN108159218A (en) | A kind of preparation method of two old extracts and its preparation with antitumor activity | |
| CN105943701B (en) | Application of qi-tonifying and blood-activating medicine in preparation of insomnia medicine | |
| CN111150816A (en) | Traditional Chinese medicine composition, compound preparation, preparation method and application of preparation | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN101628012B (en) | Medicine composition with function of regulating immunity and preparation method thereof | |
| CN107029116B (en) | Traditional Chinese medicine compound preparation for treating leukemia caused by spleen deficiency and stomach heat and preparation method | |
| CN105935439B (en) | Traditional Chinese medicine with effects of warming lung and descending turbidity and preparation method and application thereof | |
| CN105327340A (en) | Anti-senility composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication |